Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome

被引：17

作者：

Iolascon, A

Lo Cunsolo, C

Giordani, L

Cusano, R

Mazzocco, K

Boumgartner, M

Ghisellini, P

Faienza, MF

Boni, L

De Bernardi, B

Conte, M

Romeo, G

Tonini, GP

机构：

[1] Natl Inst Canc Res, Adv Biotechnol Ctr, Lab Genet Populat, I-16132 Genoa, Italy

[2] Giannina Gaslini Childrens Hosp, Dept Haematol Oncol, Genova, Italy

[3] Natl Inst Canc Res, Adv Biotechnol Ctr, Clin Epidemiol Unit, I-16132 Genoa, Italy

[4] Giannina Gaslini Childrens Hosp, Genet Lab, Genova, Italy

[5] Giannina Gaslini Childrens Hosp, Lab Oncol, Genova, Italy

[6] Univ Bari, Dept Biomed Evolut Age, Genova, Italy

来源：

CANCER LETTERS | 1998年 / 130卷 / 1-2期

关键词：

neuroblastoma; microsatellite; chromosome; 1; loss of heterozygosity; MYCN amplification;

D O I：

10.1016/S0304-3835(98)00122-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We studied chromosome Ip loss of heterozygosity (1p-LOH) in 53 neuroblastomas (NBs) using 15 (CA)n repeat loci, which covered a region of 90 cM. We also assessed chromosome 1p36 deletion by fluorescence in situ hybridization (FISH) on interphase nuclei. 1p-LOH was found in 19 (36%, 95% confidence interval (CI) 23-50%) NBs. We detected interstitial and large deletion in both localized and disseminated tumours and in one tumour of a patient at stage 4S. Allelic loss was frequently observed in 1p36 and 1p32 regions. In patients older than 1 year of age (53 Versus 13%, P < 0.002) we detected significant chromosome 1p deletion and it was associated with MYCN amplification (P = 0.001). Overall survival (OS) analysis showed that 1p-LOH is predictive of a poor outcome (odds ratio 16.5, 95% CI 5.4-50.9%); therefore, 1p-LOH should be regarded as an additional tumour progression marker in neuroblastoma. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：83 / 92

页数：10

共 42 条

[1]

AMLER LC, 1993, RECENT ADV CLIN GENE, P87

[2]

[Anonymous], 1980, STAT METHODS CANC RE

[3]

[Anonymous], 1982, EPIDEMIOLOGIC RES

[4]

BRODEUR GM, 1981, CANCER RES, V41, P4678

[5] GENE AMPLIFICATION IN HUMAN NEUROBLASTOMAS - BASIC MECHANISMS AND CLINICAL IMPLICATIONS [J].

BRODEUR, GM ;

SEEGER, RC .

CANCER GENETICS AND CYTOGENETICS, 1986, 19 (1-2) :101-111

[6] INTERNATIONAL CRITERIA FOR DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT IN PATIENTS WITH NEURO-BLASTOMA [J].

BRODEUR, GM ;

SEEGER, RC ;

BARRETT, A ;

BERTHOLD, F ;

CASTLEBERRY, RP ;

DANGIO, G ;

DEBERNARDI, B ;

EVANS, AE ;

FAVROT, M ;

FREEMAN, AI ;

HAASE, G ;

HARTMANN, O ;

HAYES, FA ;

HELSON, L ;

KEMSHEAD, J ;

LAMPERT, F ;

NINANE, J ;

OHKAWA, H ;

PHILIP, T ;

PINKERTON, CR ;

PRITCHARD, J ;

SAWADA, T ;

SIEGEL, S ;

SMITH, EI ;

TSUCHIDA, Y ;

VOUTE, PA .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) :1874-1881

[7]

CHENG NC, 1995, ONCOGENE, V10, P291

[8]

Cheng NC, 1996, ONCOGENE, V13, P1737

[9] A comprehensive genetic map of the human genome based on 5,264 microsatellites [J].

Dib, C ;

Faure, S ;

Fizames, C ;

Samson, D ;

Drouot, N ;

Vignal, A ;

Millasseau, P ;

Marc, S ;

Hazan, J ;

Seboun, E ;

Lathrop, M ;

Gyapay, G ;

Morissette, J ;

Weissenbach, J .

NATURE, 1996, 380 (6570) :152-154

[10]

ENOMOTO H, 1994, ONCOGENE, V9, P2785

← 1 2 3 4 5 →